These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31912537)

  • 1. Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.
    Schutz C; Chirehwa M; Barr D; Ward A; Janssen S; Burton R; Wilkinson RJ; Shey M; Wiesner L; Denti P; McIlleron H; Maartens G; Meintjes G
    Br J Clin Pharmacol; 2020 May; 86(5):966-978. PubMed ID: 31912537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
    Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis.
    Abdelgawad N; Chirehwa M; Schutz C; Barr D; Ward A; Janssen S; Burton R; Wilkinson RJ; Shey M; Wiesner L; McIlleron H; Maartens G; Meintjes G; Denti P
    Wellcome Open Res; 2022; 7():72. PubMed ID: 37008250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients.
    Nardotto GHB; Bollela VR; Rocha A; Della Pasqua O; Lanchote VL
    Clin Transl Sci; 2022 Feb; 15(2):514-523. PubMed ID: 34670022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
    Trentalange A; Borgogno E; Motta I; Antonucci M; Pirriatore V; Costa C; Rossi G; Barco A; De Nicolò A; Piccioni P; D'Avolio A; Bonora S; Di Perri G; Calcagno A
    Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
    Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
    Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
    Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
    Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America.
    TB:HIV Study writing Group
    AIDS; 2017 Jan; 31(3):375-384. PubMed ID: 28081036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
    Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
    Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.
    Kwara A; Enimil A; Gillani FS; Yang H; Sarfo AM; Dompreh A; Ortsin A; Osei-Tutu L; Kwarteng Owusu S; Wiesner L; Norman J; Kurpewski J; Peloquin CA; Ansong D; Antwi S
    J Pediatric Infect Dis Soc; 2016 Dec; 5(4):356-365. PubMed ID: 26407268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes.
    Ramachandran G; Chandrasekaran P; Gaikwad S; Agibothu Kupparam HK; Thiruvengadam K; Gupte N; Paradkar M; Dhanasekaran K; Sivaramakrishnan GN; Kagal A; Thomas B; Pradhan N; Kadam D; Hanna LE; Balasubramanian U; Kulkarni V; Murali L; Golub J; Gupte A; Shivakumar SVBY; Swaminathan S; Dooley KE; Gupta A; Mave V;
    Clin Infect Dis; 2020 Mar; 70(7):1463-1470. PubMed ID: 31075166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does AIDS impair the absorption of antituberculosis agents?
    Taylor B; Smith PJ
    Int J Tuberc Lung Dis; 1998 Aug; 2(8):670-5. PubMed ID: 9712282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.